Renal Cancer Research Review, Issue 8

In this issue:

HIF-2 α inhibitor in patients with advanced clear cell RCC
Atezolizumab + bevacizumab for metastatic RCC with variant histology and/or sarcomatoid features
Outcomes in patients undergoing nephrectomy following immune checkpoint inhibitors for RCC
Optimisation of pazopanib exposure by splitting dosing intake moments
Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic RCC
α(1,3)Gal-expressing allogeneic RCC immunotherapy in patients with refractory metastatic RCC
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
IL-2 chronotherapy for metastatic RCC
Safety and efficacy of restarting ICIs after irAEs in metastatic RCC
Nivolumab in patients with metastatic RCC and chronic HCV infection

Please login below to download this issue (PDF)

Subscribe